Jefferies Group Comments on Gemphire Therapeutics Inc’s FY2018 Earnings (GEMP)

Gemphire Therapeutics Inc (NASDAQ:GEMP) – Equities researchers at Jefferies Group raised their FY2018 earnings per share (EPS) estimates for Gemphire Therapeutics in a note issued to investors on Tuesday. Jefferies Group analyst M. Andrews now anticipates that the company will earn ($1.93) per share for the year, up from their previous estimate of ($2.04). Jefferies Group also issued estimates for Gemphire Therapeutics’ FY2019 earnings at ($1.59) EPS, FY2020 earnings at ($1.47) EPS, FY2021 earnings at ($1.42) EPS and FY2022 earnings at ($0.45) EPS.

Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.14).

A number of other analysts have also recently commented on the company. Canaccord Genuity reissued a “buy” rating and issued a $31.00 price target on shares of Gemphire Therapeutics in a research report on Monday, October 23rd. Roth Capital restated a “buy” rating and issued a $30.00 price objective on shares of Gemphire Therapeutics in a report on Friday, December 22nd. Piper Jaffray Companies restated an “overweight” rating and issued a $22.00 price objective on shares of Gemphire Therapeutics in a report on Friday, October 27th. Zacks Investment Research lowered shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 17th. Finally, HC Wainwright boosted their price objective on shares of Gemphire Therapeutics from $22.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, January 26th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $23.17.

Shares of Gemphire Therapeutics (NASDAQ GEMP) traded up $0.55 on Thursday, hitting $6.75. The stock had a trading volume of 350,800 shares, compared to its average volume of 131,663. The company has a current ratio of 4.17, a quick ratio of 4.17 and a debt-to-equity ratio of 1.00. Gemphire Therapeutics has a 12-month low of $6.07 and a 12-month high of $21.59.

In other news, insider Steven R. Ph.D. Gullans acquired 71,429 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average cost of $7.00 per share, for a total transaction of $500,003.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 34.00% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in Gemphire Therapeutics during the 4th quarter valued at $120,000. Advisory Services Network LLC purchased a new stake in Gemphire Therapeutics during the 2nd quarter valued at $139,000. Vanguard Group Inc. raised its stake in Gemphire Therapeutics by 137.6% during the 2nd quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock valued at $399,000 after buying an additional 17,892 shares during the last quarter. Comerica Bank purchased a new stake in Gemphire Therapeutics during the 3rd quarter valued at $850,000. Finally, Cambridge Investment Research Advisors Inc. raised its stake in Gemphire Therapeutics by 4.5% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 159,964 shares of the company’s stock valued at $1,520,000 after buying an additional 6,900 shares during the last quarter. Institutional investors own 27.54% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Jefferies Group Comments on Gemphire Therapeutics Inc’s FY2018 Earnings (GEMP)” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/15/jefferies-group-comments-on-gemphire-therapeutics-incs-fy2018-earnings-gemp.html.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Earnings History and Estimates for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply